Enhanced endocannabinoid signaling modulates neuronal network dynamics in the hippocampus by Stepan, Jens
Aus demMax-Planck-Institut für Psychiatrie
Abteilung für Translationale Forschung in der Psychiatrie
Direktorin: Prof. Dr. Elisabeth Binder
Enhanced Endocannabinoid Signaling Modulates Neuronal
Network Dynamics in the Hippocampus
Dissertation
zum Erwerb des Doktorgrades
an der Medizinischen Fakultät der
Ludwig-Maximilians-Universität München
vorgelegt von
Jens Stepan
aus
Bremen
2018
Mit Genehmigung der Medizinischen Fakultät
der Universität München
Berichterstatterin:
Priv. Doz. Dr. med. Angelika Erhardt
Mitberichterstatter:
Prof. Dr. Nikolaos Koutsouleris
Priv. Doz. Dr. Johannes Levin
Mitbetreuung durch die promovierten Mitarbeiter:
Priv. Doz. Dr. rer. nat. Carsten Wotjak
Dr. rer. nat. Matthias Eder
Dekan:
Prof. Dr. med. dent. Reinhard Hickel
Tag der mündlichen Prüfung:
26.04.2018
ii
iii
Contents
Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vi
List of Tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . viii
List of Figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . x
Zusammenfassung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xi
Eidesstattliche Versicherung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xii
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xiii
1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1 The endocannabinoid-system (ECS) . . . . . . . . . . . . . . . . . . . . . . 3
1.2 The hippocampus (HIP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.3 Foundations of voltage-sensitive-dyes . . . . . . . . . . . . . . . . . . . . . 9
2 Aims of the thesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
3 Material and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
3.1 Animals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
3.2 Preparation and staining of brain slices . . . . . . . . . . . . . . . . . . . . 14
3.3 Brain slice experiments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.4 Voltage-sensitive dye imaging (VSDI) . . . . . . . . . . . . . . . . . . . . . 15
3.5 Processing and quantification of VSDI data . . . . . . . . . . . . . . . . . . 16
3.6 Electrical stimulation techniques . . . . . . . . . . . . . . . . . . . . . . . . 17
3.7 Chemicals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
3.8 Statistics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
4.1 Opposing effects of diazepam and AM404 on HTC-Waves . . . . . . . . . 21
4.2 AM404 effects are mediated by D1R positive neurons . . . . . . . . . . . . 23
4.3 Hippocampal subregion specific drug effects . . . . . . . . . . . . . . . . . 24
iv
5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
6 Bibliography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
7 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
7.1 Chemicals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
v
Abbreviations
2-AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2-arachidonylglycerol, page 3
ACSF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . artificial cerebrospinal fluid, page 18
AD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . antidepressant, page 1
AEA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N-arachidonoyl-ethanolamine, page 3
AXDs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . anxiety disorders, page 1
BDZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . benzodiazepines, page 2
BIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . bicuculline methiodide, page 14
CA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . cornu ammonis, page 6
CB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . cannabinoid, page 3
CB1R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . cannabinoid 1 receptor, page 3
CB2R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . cannabinoid 2 receptor, page 3
CBR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . cannabinoid receptor, page 3
CCD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . charged coupled device, page 15
D1R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . dopamine 1 receptor, page 13
DG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . dentate gyrus, page 6
DMSO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . dimethyl sulfoxide, page 14
DSE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . depolarization induced-suppression of excitation,
page 5
DSI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . depolarization induced-suppression of inhibition,
page 5
EC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . entorhinal cortex, page 6
eCB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . endocannabinoids, page 3
eCB-LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . endocannabinoid-mediated long-term depression,
page 5
eCB-STD . . . . . . . . . . . . . . . . . . . . . . . . . . . endocannabinoid-mediated short-term depression,
page 5
ECS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . endocannabinoid-system, page 2
FAAH-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . fatty acid amide hydrolase-1, page 4
FDS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . fast depolarization-mediated signal, page 17
GABA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . gamma-aminobutyric acid, page 2
GCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . granule cell layer, page 8
GPCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-protein coupled receptor, page 3
vi
HF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hippocampal formation, page 6
HIP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hippocampus, page 2
HPA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hypothalamic-pituitary-adrenal, page 29
HTC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hippocampal trisynaptic circuit, page 9
KO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . knockout, page 13
LEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . lateral entorhinal cortex, page 7
LTP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . long-term potentiation, page 28
MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . major depression, page 1
MEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . medial entorhinal cortex, page 7
MGL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . monoacylglycerol lipase, page 4
ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . molecular layer, page 7
MPIP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Max Planck Insitute of Psychiatry, page 13
PARA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . parasubiculum, page 6
PCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . pyramidal cell layer, page 8
PL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . polymorphic layer, page 8
PP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . perforant pathway, page 8
PRE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . presubiculum, page 6
ROI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . region of interest, page 16
SL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . stratum lucidum, page 8
SLM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . stratum lacunosum-moleculare, page 8
SO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . stratum oriens, page 8
SR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . stratum radiatum, page 8
SRPDs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . stress-related psychiatric disorders, page 1
SSRIs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . selective serotonine reuptake inibitors, page 1
SUB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . subiculum, page 6
TCAs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . tricyclic antidepressants, page 1
TRPV1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . transient potential receptor of vanniloid 1, page 4
USA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . United States of America, page 14
VSDI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . voltage-sensitive-dye imaging, page 10
WT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . wild-type, page 13
vii
List of Tables
7.1 Chemicals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
viii
List of Figures
1.1 Endocannabinoid-mediated short-term depression (eCB-STD) . . . . . . . 5
1.2 Anatomy of the hippocampal formation . . . . . . . . . . . . . . . . . . . . 7
1.3 Physical mechanism of electrochromism . . . . . . . . . . . . . . . . . . . . 10
3.1 Deafferentiations in hippocampal brain slices . . . . . . . . . . . . . . . . . 15
3.2 Voltage-sensitive dye imaging setup . . . . . . . . . . . . . . . . . . . . . . 16
3.3 Quantification of VSDI signals . . . . . . . . . . . . . . . . . . . . . . . . . . 17
4.1 Experimental setup for recordings of polysynaptic activity flow through
the HTC network . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
4.2 Anatomical position of ROIs and experimental protocol . . . . . . . . . . . 20
4.3 Hippocampal activities in response to 5 Hz EC/DG-input . . . . . . . . . 21
4.4 DMSO effect on HTC-Waves . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
4.5 Diazepam effect on HTC-Waves . . . . . . . . . . . . . . . . . . . . . . . . . 22
4.6 AM404 effect on HTC-Waves . . . . . . . . . . . . . . . . . . . . . . . . . . 23
4.7 CB1Rs on D1R positive neurons mediate AM404 effects . . . . . . . . . . . 24
4.8 CA3/CA1 activity ratios are drug specific . . . . . . . . . . . . . . . . . . . 25
ix
Enhanced Endocannabinoid Signaling Modulates Neuronal
Network Dynamics in the Hippocampus
Abstract
The incidence of stress-related psychiatric disorders (SRPDs) such as major depression
(MD), or anxiety disorders is constantly rising, while there is no effective and reliable
pharmacotherapy. A breakthrough is not yet in sight and even worse, many pharmaceu-
tical companies have stopped their drug development programs. This precarious situ-
ation affecting patients, therapists, and healthcare systems is caused by the demanding
complexity of the mammalian brain, and its constant adaption to a variable environment.
Current theories of SRPD aetiology involve multilevel dysregulation of molecular, cellu-
lar and neural circuit mechanisms. The endocannabinoid system (ECS) has a primary
role in brain homeostasis, is altered in stress-related psychiatric disorders and appears
as a new target for more efficient drugs. ECS modulator-induced behavioral changes are
linked to hippocampal activity, but the alterations in millisecond-scale brain circuit dy-
namics that govern their cellular and molecular actions are largely unknown. Using a re-
cently developed voltage-sensitive dye imaging assay in mouse brain slices it was tested,
if the benzodiazepine diazepam and the endocannabinoid neurotransmission enhancer
AM404modulate neuronal activity propagation through the hippocampal trisynaptic cir-
cuit ("HTC": perforant path ! dentate gyrus ! area CA3 ! CA1). While diazepam
clearly reduced activity propagation through the HTC network ("HTC-Waves"), AM404
facilitated HTC-Waves in CA regions which was absent in mice lacking the expression
of CB1 receptors on D1-receptor positive neurons. Collectively, these results show bidi-
rectional drug effects on the HTC network, partly mediated via activity of a genetically
defined neural population and point to the ECS as a therapeutic node for intervening
with SRPDs.
x
Verstärkung der Endocannabinoid-vermittelten
Neurotransmission moduliert die Netzwerkaktivität im
Hippokampus
Zusammenfassung
Die Inzidenz von stress-assoziierten, psychischen Erkrankungen (SRPDs) wie Depress-
ionen oder Angststörungen steigt stetig; eine effektive und zuverlässige medikamentöse
Behandlung gibt es jedoch nicht. Ein Durchbruch ist nicht zu erwarten und schlimmer
noch, viele pharmazeutische Unternehmen haben ihre entsprechenden Programme zur
Medikamentenentwicklung gestoppt. Diese prekäre Situationmit Auswirkungen auf Pa-
tienten, Therapeuten und Gesundheitssysteme ist auf die Komplexität und ständige An-
passung des Säugergehirns zurückzuführen. Aktuelle Theorien zur Ätiologie von SRPDs
beinhalten eine vielschichtige Dysregulation von molekularen Prozessen, zellulären Me-
chanismen und neuronalen Netzwerken. Das Endocannabinoidsystem (ECS) könnte ein
neuer Ansatzpunkt für effektivereMedikamente sein, da es den Stoffwechsel des Gehirns
maßgeblich beeinflusst und bei SRPDs in seiner Funktion beeinträchtigt ist. DurchModu-
latoren des ECS hervorgerufene Verhaltensänderungen stehen in Zusammenhang mit
der neuronalenAktivität imHippokampus (HIP). Dennoch ist über die zeitlich-räumliche
Dynamik neuronaler Aktivität in Hirnschaltkreisen, welche durch Prozesse auf zellulärer
und molekularer Ebene hervorgerufen wird, wenig bekannt. Daher wurde in dieser Ar-
beit mit Hilfe eines kürzlich entwickelten Bildgebungsverfahren, das auf der Verwen-
dung spannungssensitiver Farbstoffe basiert, untersucht, ob das BenzodiazepinDiazepam
und der Verstärker der endocannabinoid-vermittelten Neurotransmission, AM404, den
Aktivitätsfluss durch den trisynaptischen Schaltkreis des HIP ("HTC": perforant path
! dentate gyrus ! area CA3 ! CA1) verändern. Diazepam reduziert den Aktivitäts-
fluss im HTC-Netzwerk ("HTC-Wellen"), während AM404 eine Verstärkung der HTC-
Wellen hervorruft. Letzterer Effekt ist bei Mäusen ohne CB1 Rezeptoren auf D1 positiven
Nervenzellen nicht nachweisbar. Zusammengefasst zeigen diese Ergebnisse diametrale
Medikamenteneffekte im HTC-Netzwerk, die teilweise auf der Aktivität einer genetisch
definierten Nervenzellpopulation basieren, und sie deuten auf eine wichtige Rolle des
ECSs als therapeutisches Ziel zur Behandlung von SRPDs hin.
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Chapter 1
Introduction
The causes of stress-related psychiatric disorders (SRPDs) including extremely debilitat-
ing diseases such as anxiety disorders (AXDs) andmajor depression (MD) remain largely
unknown (Holsboer, 2008; Klengel and Binder, 2015). They significantly contribute to
mortality andmorbidity worldwidewith a combined lifetime risk of around 30% (Kessler
et al., 2005; Ressler and Mayberg, 2007; Steel et al., 2014). A cause or cure and objective
diagnostic tests for SRPDs are missing because the underlying changes in brain function
remain largely unknown (Cai et al., 2013). This fosters chronic illness, with significant
emotional impact on patients, such that SRPDs are responsible for serious and constantly
increasing constraints on healthcare systems (WHO, 2004). This lack of knowledge is
mainly attributable to the multifactorial character of SRPDs, influenced by both genetic
predisposition and environmental factors (Klengel and Binder, 2015). The term SRPDs is
often used for various disease entities because multiple strands of evidence have identi-
fied similarities among these illnesses including: (i) stress as a common risk-factor, (ii) a
high comorbidity, and, (iii) various sharedmolecular pathways and neurocircuits (Berton
and Nestler, 2006; Ressler and Mayberg, 2007; Klengel and Binder, 2015).
Among different classes of psychotropic medication the most frequently used and first-
line treatment option for most SRPDs are antidepressant (AD)s such as selective sero-
tonine reuptake inibitors (SSRIs) and tricyclic antidepressants (TCAs) (Ravindran and
Stein, 2010). TCAs have been discovered by serendipity in the early 1950s, followed
by SSRIs in the 1970s, and both elevate monoamine levels in the synaptic cleft (Wrobel,
2007). Despite steady advances in the understanding of monoamine signaling (Cole-
man et al., 2016), even the latest innovations reaching the market are "me-too" drugs,
that is, they also inhibit monoamine reuptake from the synaptic cleft and need weeks of
administration to become clinically effective (Berton and Nestler, 2006; Reardon, 2016).
The recognition that ADs may be considered as a kind of "dirty drugs" that modulate
by far more targets than monoamine levels and the discovery of fast symptom relief in
SRPDs (Zanos et al., 2016), lead to considerable efforts on the discovery of more specific,
faster acting drugs, that modulate non monoaminergic targets such as glutamatergic,
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gamma-aminobutyric acid (GABA)ergic, neuroendocrine- and membrane-lipid derived
transmitter systems (Rammes and Rupprecht, 2007; Micale et al., 2013; Carta et al., 2014;
Zanos et al., 2016). Since all efforts have not yet succeeded in bringing any fundamentally
newmedications to the market and response rates of SRPDs to ADs are low, the pharma-
cological treatment fails in a considerable number of patients (Berton and Nestler, 2006;
Lépine and Briley, 2011; Bandelow et al., 2014; Caddy et al., 2015; Zanos et al., 2016).
Because of the time lag before SSRIs and other medication become effective clinicians
often prescribe benzodiazepines (BDZ) for acute symptom relief (Ravindran and Stein,
2010; Holsboer et al., 2012). In contrast to many other drugs they are effective imme-
diately and their mode of action is well known. They bind to a specific subunit of the
ionotropic GABAA-receptor, themost abundant inhibitory receptor throughout themam-
malian brain, resulting in an enhanced effect of the inhibitory neurotransmitter GABA
(Holsboer et al., 2012). The GABAergic system is expressed in most brain regions (Wat-
son et al., 2011). Thereby, BDZs have various effects including anxiolytic, amnesic, hyp-
notic, anticonvulsant, muscle-relaxant, and sedative actions (Ravindran and Stein, 2010;
Hoffman and Mathew, 2008). The use of BDZs, though effective, is hampered by major
side effects. From a clinical perspective, this includes over-sedation, psychomotor in-
coordination, and the risks of abuse and physiological dependence with long-term use.
Especially the well documented cognitive impairment after BDZs administration is a se-
rious problem because full cognitive performance seems to be superior for cognitive-
behavioral therapy. Therefore, BDZs are recommended only for short-term use or in
exceptional cases, e.g., suicidality and should be tapered once other medication becomes
effective (Chouinard, 2004; Ravindran and Stein, 2010).
The endocannabinoid-system (ECS) is supposed to play a major role in SRPDs, thus,
emerging as a target for the development of new drugs to treat these brain-based diseases
more effectively (Hillard et al., 2012; Micale et al., 2013; Lutz et al., 2015). ECSs modula-
tors were ascribed anxiolytic and antidepressant actions (Micale et al., 2013; Singewald
et al., 2015; Pertwee, 2015; Rubino et al., 2015). A brain structure that is intimately linked
to SRPDs with high expression levels of the ECS and therefore a potential target of ECS
modulators is the hippocampus (HIP) (Krishnan and Nestler, 2008; Pertwee, 2015). But,
the ECS represents a complex neurotransmitter-system and likewise ADs, pharmacologi-
cal manipulation induces various molecular, cellular and structural changes (Kano, 2014;
Pertwee, 2015). Recent research suggests, that it is difficult to integrate these mani-
fold changes on the "microscale" for outcome prediction on the neuronal network level
("mesoscale") or even behavior ("macroscale"; Airan et al., 2007; Avrabos et al., 2013;
Lewis and Lazar, 2013; Stepan et al., 2015b). Therefore, more circuit-centered approaches
like voltage-imaging, calcium-imaging and optogenetics moved into the focus of neu-
roscience research and seem to be well suited to probe the functional aspects of "dirty-
drugs" like ECS-modulators or ADs (Karayiorgou et al., 2012; Stepan et al., 2015b).
1.1. THE ENDOCANNABINOID-SYSTEM (ECS) 3
1.1 The endocannabinoid-system (ECS)
What is now known as the ECS is, like other neurotransmitter-systems, formed by dis-
tinct elements that enable signal transduction at chemical synapses and was started to
be scientifically characterized in the 1960s (Bear and Paradiso, 2016; Mechoulam et al.,
2014). These are: (1) at least two seven transmembrane domain-containing Gi/o-protein
coupled cannabinoid receptor (CBR)s, cannabinoid 1 receptor (CB1R) and cannabinoid 2
receptor (CB2R), that modulate diverse targets and appending signal transduction path-
ways (Matsuda et al., 1990; Munro et al., 1993), (2) several endogenous (hence endo-
cannabinoids (eCB)) ligands of CBR, with the two best characterized and most abundant
being N-arachidonoyl-ethanolamine (AEA) (anandamide) and 2-arachidonylglycerol (2-
AG) (Devane et al., 1992; Mechoulam et al., 1995; Sugiura et al., 1995), (3) enzymes and
processes responsible for the biosynthesis and removal or degradation of eCB (Di Marzo
and De Petrocellis, 2012; Castillo et al., 2012; Pertwee, 2015; Cascio and Marini, 2015).
The ECS modulates neurotransmission between multiple cell types in the brain, thereby
regulating neuronal network activity and finally behavioral outputs. Because the ECS is
also present in non neuronal tissue a variety of physiological processes have been identi-
fied that are modulated by eCB including immune response, cardiovascular function and
metabolism (Marsicano and Lutz, 1999; Lutz et al., 2015; Krentz et al., 2016). Especially
its role in the control of appetite, energy expenditure and aspects of glucose and lipid
metabolism is worth mentioning, since the selective, inverse CB1R-agonist SR141716 Ri-
monabant is one of the few drugs targeting the ECS that has been approved for phar-
macological support of weight reduction in 2006 (Krentz et al., 2016). But, already 2009
Rimonabant waswithdrawn from themarket due to psychiatric adverse events including
anxiety, depression and suicidal ideation, supporting the ECSs diverse impact on phys-
iological processes (Krentz et al., 2016). Although many researchers studied the compo-
nents and function of the ECS and the topic attracted a great deal of attention in public be-
cause it is responsible for the effects of the cannabinoid (CB) delta-tetrahydrocannabinol
(THC) which mediates the psychotropic activity of marijuana (cannabis sativa), the pre-
cise function of the ECS remains elusive (Gaoni andMechoulam, 1971;Micale et al., 2013).
The CB1R is perhaps the most common G-protein coupled receptor (GPCR) through-
out the mammalian brain and is predominantly found at presynaptic terminals of cen-
tral and peripheral neurons. It is highly expressed in cortical areas, amygdala, striatum,
and cerebellum. CB1Rs were found in several neuronal subtypes at different expressions
levels including glutamatergic, cholinergic, GABAergic, dopaminergic, noradrenergic,
and serotonergic neurons, with highest levels in GABAergic neurons, but also in glia
cells and microglia which are important for synthesis and degradation of eCB. Expres-
sion patterns also differ across subregions suggesting a complex mechanism to underlie
the modulatory effects of eCB likely explaining their diverse effects on multiple phys-
iological processes (Marsicano and Lutz, 1999; Haring et al., 2012; Micale et al., 2013;
Pertwee, 2015). The CB2R was supposed to be mainly expressed outside of the nervous
system, but recent research suggests its presence in glial cells and neurons of several brain
regions such as amygdala, HIP and cerebral cortex (Hu and Mackie, 2015; Pertwee, 2015;
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Stempel et al., 2016). In a recent study Stempel et al. (2016) describe a CB2R-mediated cell
type-specific plasticity mechanism in the HIP that provides evidence for their neuronal
expression and highlights their importance in neurotransmission (Stempel et al., 2016).
A third CBR (CB3R) was also reported, but to date its role in regulating body function
has not been definitively established (Micale et al., 2013).
Aside AEA and 2-AG, several other endogenous compounds that can activate or block
cannabinoid receptors either orthosterically or allosterically were identified including
noladin ether, virodhamine, dihomo-g-linolenoylethanolamide, sphingosine, docosate-
traenoylethanolamide, N-arachidonoyldopamine, eicosapentaenoyleth- anolamide, do-
cosahexaenoylethanolamide, N-oleoyldopamine and oleamide (Pertwee, 2015). Con-
versely, non-CBR-mediated pharmacological actions of eCB were reported. AEA and
2-AG bind to other GPCRs (GPR55, Muscarinic M1/M4, Adenosine A3, 5-HT1/5-HT2),
ligand-gated ion channels (5-HT3, nicotinic, glycine, NMDA, GABAA), ion-gated ion
channels (T-type calcium Cav3, 2TM potassium KATP, 6TM potassium Kv), TRP chan-
nels (transient potential receptor of vanniloid 1 (TRPV1) (non- selective cation channel,
to which vanilloids such as capsaicin bind), TRPM8) nuclear receptors a (PPAR-a) and
g (PPAR-g) (Di Marzo and De Petrocellis, 2012; Pertwee, 2015). An important difference
between the twomost studied eCBs, 2-AG and AEA, are the metabolic pathways that un-
derlie their biosynthesis and degradation (Di Marzo and De Petrocellis, 2012). Although
contradicting results were reported (Hashimotodani et al., 2013), both classical eCBs are
usually produced on demand in postsynaptic sites, in response to elevation of intracellu-
lar Ca2+. AEA is synthesized from phosphatidylethanolamines on various biosynthetic
pathways in a multistep process involving several, partly, yet not identified enzymes in-
cluding N-acyl-phosphatidylethanolamine specific phospholipase D (NAPE-PLD), a,b-
hydrolase- 4 (ABHD4), glycerophosphodiesterase-1 (GDE1), an as-yet-unidentified phos-
pholipase C (PLC) and other phosphatases. The most accepted pathway in the formation
of 2-AG by hydrolysis of membrane phospholipids is catalyzed by the consecutive action
of phospholipase Cb (PLCb) and diacylglycerol lipase a (DGLa). AEA and 2-AG break-
down is catalyzed by intracellular enzymes, this is primarily monoacylglycerol lipase
(MGL) and to a lesser extend a,b-hydrolase-6 (ABHD6), a,b-hydrolase-12 (ABHD12) for
2-AG and fatty acid amide hydrolase-1 (FAAH-1) for AEA. Furthermore, a hitherto not
clearly identified membrane transporter for cellular uptake of eCBs has been reported,
but its existence and putative mode of action is still a matter of debate (Glaser et al., 2003;
Di Marzo and De Petrocellis, 2012; Fowler, 2013).
The basic mechanism by which eCB modulate synaptic function is through retrograde
signaling. This mode of synaptic transmission is best characterized in the ECS where
elevation of intracellular Ca2+ upon postsynaptic depolarization, activation of Gq/11-
coupled and other receptors triggers de-novo synthesis of eCB (Figure 1.1). Subsequently,
eCBs move retrogradely across the synapse by a unknown mechanism, bind presynaptic
CB1Rs, and suppress neurotransmitter release by activation of A-type and inwardly recti-
fying K+ channels, and by inhibition of N- and P/Q-type Ca2+ currents (Alger and Kim,
2011; Castillo et al., 2012; Ohno-Shosaku and Kano, 2014; Kano, 2014; Pertwee, 2015). This
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form of short-term synaptic plasticity is known as endocannabinoid-mediated short-term
depression (eCB-STD) or more specifically depolarization induced-suppression of inhibi-
tion (DSI) and depolarization induced-suppression of excitation (DSE) at inhibitory and
excitatory neurons, respectively (Kreitzer and Regehr, 2001; Ohno-Shosaku et al., 2001;
Wilson and Nicoll, 2001). In several brain areas including the HIP, more physiological
synaptic activity induces eCB-STD, mediated by postsynaptic AMPA receptors (Kano,
2014). A persistent reduction of transmitter release mediated by endocannabinoids is
called endocannabinoid-mediated long-term depression (eCB-LTD) (Kano, 2014). 2-AG
seems to be the principal eCB required for activity-dependent retrograde signaling which
is supported by the observation that DGLa is mainly expressed in post-synaptic dendrites
and somata, whereas CB1Rs andMGL are predominantly found in presynaptic terminals.
is then converted to 2-AG by DGLa. The Ca2+-assisted
RER accounts for the eCB-STD induced by the combi-
nation of a small increase in [Ca2+]i and weak receptor
activation, both of which can be subthreshold for triggering
endocannabinoid release. This synergistic effect can be
explained by the Ca2+ dependency of receptor-driven
PLCb stimulation [9–11] (Fig. 1(a), green arrow).
More physiological ways of inducing eCB-STD are via
synaptic activity (synaptically driven eCB-STD) [1]
(Fig. 1(b)). If glutamate is released from excitatory presyn-
aptic terminals in a sufficient amount to induce postsynaptic
Ca2+ elevation and/or mGluR activation, 2-AG is released
through the mechanism for CaER, basal RER or Ca2+-
assisted RER. Excitatory synaptic activity is therefore
potentially effective in inducing 2-AG release. Synaptically
driven eCB-STD can be either homosynaptic (Fig. 1(b), red
arrow) or heterosynaptic [1] (Fig. 1(b), blue arrow).
The standard 2-AG model described above is supported by a
considerable number of studies. DSI, DSE, receptor-driven
eCB-STD and synaptically driven eCB-STD are all inhib-
ited by pharmacological blockade of DGL [12!!] and genetic
deletion of DGLa [13–15]. The mGluR- or mAChR-driven
eCB-STD is blocked by genetic deletion of PLCb1 for
hippocampal neurons [9] or PLCb4 for cerebellar Purkinje
cells [10]. The termination of DSI/DSE is prolonged by
genetic deletion [8!!,16] and pharmacological blockade of 2-
AG hydrolyzing enzyme (MGL), but not anandamide
(another major endocannabinoid) hydrolyzing enzyme (fatty
acid amide hydrolase, FAAH) [17].
On-demand vs. pre-formed
It is generally thought that 2-AG is not stored in neurons,
but synthesized on demand upon stimulation. However,
this ‘on-demand synthesis model’ was challenged by an
alternative model that 2-AG is pre-formed by DGLa,
pooled within cells, and mobilized from this hypothetical
pre-formed 2-AG pools upon stimulation without the con-
tribution of DGLa [18,19]. This model was developed to
reconcile the apparent discrepancy in the experimental
results between genetic and pharmacological blockade of
DGL. DGLa knockout mice were generated indepen-
dently by three groups, and they all exhibit complete loss of
eCB-STD [13–15]. In contrast, the reported effects of
acute pharmacological blockade of DGL were highly con-
troversial [19]. A classical DGL inhibitor, tetrahydrolip-
statin (THL), inhibited eCB-STD in some studies, but not
in others. Inconsistent results were also observed with a
novel potent DGL inhibitor, OMDM-188. OMDM-188
failed to inhibit DSI in one study [20], whereas it inhibited
DSI but not mGluR-driven STD in another study [21].
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Molecular mechanisms of endocannabinoid-mediated short-term depression (eCB-STD). (a) The production of diacylglycerol (DG) is induced by either
a large Ca2+ elevation, which is caused by depolarization-induced activation of voltage-gated Ca2+ channels (VGCC), through unidentified mechanisms
(red arrows), or strong activation of Gq/11-coupled receptors such as mGluRs and mAChRs through PLCb (blue arrows). If weak activation of Gq/11-
coupled receptors is combined with a small Ca2+ elevation, both of which are subthreshold for DG production when given alone, receptor-driven PLCb
stimulation is enhanced by Ca2+ to produce DG (green arrow). DG is then converted to 2-AG by diacylglycerol lipase a (DGLa). 2-AG is released from
the postsynaptic neuron, and activates presynaptic CB1 receptors to suppress transmitter release (STD). 2-AG is hydrolysed mostly by presynaptic
monoacylglycerol lipase (MGL) and arachidonic acid (AA) is produced. (b) Excitatory synaptic activity releases glutamate, which activates postsynaptic
AMPA-type glutamate receptors (AMPARs) and mGluRs. Activation of AMPARs causes Ca2+ elevation through activating VGCCs. The resulting
postsynaptic Ca2+ elevation and/or mGluR activation causes the release of 2-AG through the mechanisms illustrated in a. 2-AG activates CB1
receptors on the same presynaptic terminals releasing glutamate (red arrow, homosynaptic) or neighboring terminals (blue arrow, heterosynaptic), and
suppresses transmitter release (STD).
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Fig. 1.1. Endocannabinoid-mediated short-term de-
pression (eCB-STD). Diacylglycerol (DG) is synthe-
sized by either a large Ca2+ elevation, caused by
depolarization-induced activation of voltage-gated
Ca2+ channels (VGCC) or NMDA- type glutamat-
receptor (NMDAR, not illustrated), (red arrows), or
strong activation of Gq/11-coupled receptors such as
mGluRs and AChRs through PLCb (blue arrows).
Subthreshold Ca2+ elevation and we k a tivation of
Gq/11- coupled receptors might exert synergistic ef-
fects on DG production (green arrow). DG is then
converted to 2-AG by diacylglycerol lipase a (DGLa).
2-AG is subsequently released from the postsynap-
tic neuron, and activates presynaptic CB1Rs to sup-
press transmitter release. 2-AG is predomin ntly hy-
drolyzed to arachidonic cid (AA) by the presynap-
tic and i tracellular enzyme monoacylglyc rol lip se
(MGL; a apted from Ohno-Shosaku and Kano, 2014).
The biosynthesizing enzymes of AEA are
located pre- and postsynaptically. FAAH-
1 is predominantly found in post-synaptic
locations and the enzymes are concen-
trated in intracellular membranes suggest-
ing modulation of synaptic function by
AEA in a non-retrograde, intracellular or
autocrine manner (Castillo et al., 2012;
Busquets Garcia et al., 2016). This can oc-
cur via postsynaptic TRPV1 channels and
CB1Rs on or within (e. g. mitochondria)
the postsynaptic cell (Castillo et al., 2012;
Di Marzo and De Petrocellis, 2012; Bus-
quets Garcia et al., 2016). Binding of AEA
to TRPV1 channels (AEA is a full agonist
at TRPV1 channels) received much atten-
tion because this interaction is involved in
the induction of long-term depression in
the HIP and nucleus accumbens support-
ing its hitherto questioned physiological
relevance (Chávez et al., 2010; Di Marzo,
2010). Because biosynthesis and break-
down of AEA and 2-AG are different, it
was suggested that they can act indepen-
dently and simultaneously even if expressed at the same synapse. Different expression
patterns of the ECS in distinct neuronal subpopulations, in different anatomical posi-
tions of a neuron, in specific pre-, post-, and extrasynaptic positions as w ll as ext a-
and intracellular membranes, and the finding that CBRs have more than one endoge-
nous ligand allow diverse modulation of synaptic trans ission and induction of synaptic
plasticity on various time-scales (Di Marzo and De Petrocellis, 2012; Castillo et al., 2012;
Ohno-Shosaku and Kano, 2014; Busquets Garcia et al., 2016). Moreover, the eCB itself
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undergoes plastic changes in response to diverse stimuli (Kano, 2014).
To understand how the ECS regulates physical functions and for clinical use, a vari-
ety of substances have been developed for pharmacological intervention, although to-
day no drug modulating the ECS is on the market (Micale et al., 2013). Among oth-
ers this includes agonists/anatgonists, inverse agonists, antibodies and ECS-enhancer
(Micale et al., 2013; Singewald et al., 2015). Some of these substances exert their effects
through direct interaction with CBRs like the selective, inverse CB1R-agonist SR141716
(Rimonabant; see this section above; Micale et al., 2013; Llorente-Berzal et al., 2015;
Krentz et al., 2016). ECS-enhancer reduce the activity of the enzymes or transporters
responsible for breakdown or removal of eCB thereby elevating extracellular eCB lev-
els. A widely used substance is JZL 184, an irreversible inhibitor of MGL, which can
elevate brain 2-AG-levels up to 8-fold (Micale et al., 2013). The bioactive N-acylamine
AM404, a metabolite of the analgesic Acetaminophen (paracetamol; Hogestatt et al.,
2005) is another prototypical eCB transport inhibitor with fear-alleviating/anxiolytic ef-
fects in several animal models and was used in the present study (see also Results (4.2)
and Discussion (5); Beltramo et al., 1997; Zygmunt et al., 2000; Hogestatt et al., 2005;
Micale et al., 2013). Like all other ECS-enhancer AM404 has the disadvantage, that its
exact mode of action is not fully understood, likely due to the complexity of the ECS
itself, its polypharmacological profile and potential interaction with other neurotrans-
mitter systems (Micale et al., 2013; Pertwee, 2015; Singewald et al., 2015).
1.2 The hippocampus (HIP)
Because the HIP has anatomical features that have been a fertile ground for circuit-
centered approaches and is a focus of psychiatric and eCB research, experiments were
conducted in this limbic brain region (Marsicano and Lutz, 1999; Airan et al., 2007; Ressler
and Mayberg, 2007; Stepan et al., 2012). Moreover, recent research points to the HIP as a
potential target of eCB-modulators for pharmacoaugmentation of psychotherapies (e. g.
exposure-based therapies; see also Discussion (5)).
The HIP is a part of the hippocampal formation (HF), which is formed by six cytoar-
chitectonically distinct subregions including the dentate gyrus (DG), the ammon’s horn
(cornu ammonis (CA), with its subregions CA3, CA2 and CA1), the subiculum (SUB), the
presubiculum (PRE), the parasubiculum (PARA), and the entorhinal cortex (EC) (Figure
1.2; Amaral and Witter, 1989).
The mouse HIP (here: DG and CA-subregions), is a long, curved structure lying in
the temporal lobe of each hemisphere. It has a transverse axis ranging from the DG
to CA-subregions (running in parallel to the cell layer) and a longitudinal, dorsoven-
tral or septotemporal axis running from the septal nuclei rostrally to the temporal cor-
tex ventrocaudally (Figure 1.2; Amaral and Witter, 1989; Amaral, 1993; Andersen et al.,
2006). Multilevel analyses (genetic, molecular, behavior, functional and circuit) sug-
gest a functional segmentation of the HIP along its rostral/caudal axis with roughly
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Fig. 1.2. Anatomy of the hippocampal formation. Expansion of the c-shaped HIP from the septal nuclei
(S) to the temporal cortex (T) in the rodent brain (adapted from Amaral and Witter, 1989). The outtake
illustrates a transverse section (TRANS) through the HIP (adapted from Stepan, 2015). Abbreviations: CA,
cornu ammonis; GCL, granule cell layer; DG, dentate gyrus; LEC, lateral entorhinal cortex; MEC, medial
entorhinal cortec; ML, molecular layer; PARA, parasubiculum; PCL, pyramidal cell layer; PL, polymorphic
layer; PRE, presubiculum; SL, stratum lucidum; SLM, stratum lacunosum moleculare; SO, stratum oriens;
SR, stratum radiatum; SUB, subiculum.
three subdivisions: dorsal/rostral (septal pole), intermediate, and ventral/caudal (tem-
poral pole). The dorsal part is typically associated with cognitive functions like learn-
ing and memory or spatial navigation, whereas the ventral part is supposed to pro-
cess information associated with stress, emotion and affect (Fanselow and Dong, 2010;
Strange et al., 2014). More recently, a model that incorporates functional longitudinal-axis
gradients, superimposed on discrete functional domains, provides a potential framework
to explain the multiple functions ascribed to the HIP more precisely (Strange et al., 2014).
In the EC, six sublayers are usually distinguished. Five of them are dominated by cell
bodies, the most superficial one is called molecular layer (ML) and predominantly con-
tains axons. Although this building plan is similar to the neocortex, the most prominent
excitatory projection cells in the EC are stellate cells and pyramidal cells located in layers
II and III. Distinct anatomical features and connectivity patterns as well as functional dif-
ferences divide the EC into a medial part (medial entorhinal cortex (MEC)) and a lateral
part (lateral entorhinal cortex (LEC); Figure 1.2; Hafting et al., 2005; Andersen et al., 2006;
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Patton and McNaughton, 1995; Watson et al., 2011; Stepan, 2015).
A prominent and recognizable feature of the DG is a "U"-shaped appearance in ventral
parts, and a more "V"-shaped appearance in dorsal parts. Approximately one third of the
DGs longitudinal extent is located between areas CA1 and CA3 and is called suprapyra-
midal or inner blade. Next follows the middle third, located at the kink of the "V" or
"U", which is called the crest. The main input region of the HIP is completed by the
last third, inferior to area CA3, which is called infrapyramidal or outer blade (Figure 1.2;
Amaral et al., 2007; Claiborne et al., 1986; Patton and McNaughton, 1995; Witter, 2007;
Stepan, 2015). The DG is composed of three layers which are usually divided into a deep
layer adjacent to CA3 (hilus or polymorphic layer (PL)), a principal cell layer (granule
cell layer (GCL)) with characteristic, densely packed granule cells, and a superficial ML.
The GCL and ML are sometimes summarized as fascia dentata. The ML contains the
perforant pathway (PP), an important axon bundle that conveys information to all sub-
regions of the HIP. More specifically, it is formed by axons from EC layer II/III cells,
which provide excitatory synaptic input on apical dendrites of DG granule cells (Fig-
ures 1.2, 4.1; Amaral et al., 2007; Patton and McNaughton, 1995; Claiborne et al., 1986;
Watson et al., 2011; Witter, 2007; Stepan, 2015).
The CA is usually described as having three layers: A deep layer called stratum oriens
(SO), characterized by the presence of the principal cells basal dendrites. A middle and
most prominent layer, the pyramidal cell layer (PCL) or principle cell layer and a ML.
The ML is divided into distinct sublayers that differ across CA subregions: (1) stra-
tum lucidum (SL), containing proximal apical dendrites of pyramidal cells and is only
present in areas CA2 and CA3; (2) stratum radiatum (SR), containing the distal apical
dendrites of pyramidal neurons; (3) stratum lacunosum-moleculare (SLM) adjacent to
the hippocampal fissure, comprising the pyramidal neurons apical tufts of the apical
dendrites (Figure 1.2; Andersen et al., 2006; Kohara et al., 2014; van Strien et al., 2009;
Stepan, 2015). Primarily neurons in deep layers IV and V of the EC receive informa-
tion comming back from hippocampal output regions area CA1 and the subiculum. EC
layer IV and V neurons subsequently project to superficial layers or high-order asso-
ciation cortices. EC layer II neurons also send axons via the PP directly to areas CA3
and CA2. Another input to the HIP emerges from EC layer III neurons projecting via
the temporoammonic pathway (part of the PP) exclusively to the CA1 subfield and the
subiculum. This circuitry suggests the EC to be the major hub between the HIP and other
cortical regions (Figure 1.2, Witter et al., 2000; van Strien et al., 2009; Kohara et al., 2014;
Stepan et al., 2015a).
In contrast to the reciprocal connectivity of most other cortical structures the anatomi-
cal features described above facilitate a unidirectional passage of information through
the entorhinal-hippocampal loop via several parallel pathways. Before entering the HIP,
polymodal sensory information is funneled through a hierarchically organized neocor-
tical network and is subsequently fed into the EC, mainly to superficial layers II and
III (Andersen et al., 2006; Teyler and Rudy, 2007; Stepan et al., 2015a; Backus et al.,
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2016). Subsequently activated DG granule cells give rise to mossy fibers, the most promi-
nent non-commissural/ associational excitatory innervation of CA3 pyramidal neurons.
These cells in turn synapse via the glutamatergic Schaffer collaterals onto ipsilateral CA1
pyramidal neurons, thereby completing a highly topologically arranged loop of informa-
tion flow, the hippocampal trisynaptic circuit (HTC) (Amaral and Witter, 1989; Kohara et
al., 2014; Stepan et al., 2015a). Its prominent anatomical appearance and well-established
role in various cognitive processes argues for the HTC as the main route of information
flow through the HIP (Nicoll and Schmitz, 2005; Nakashiba et al., 2008; Neves et al., 2008;
Daumas et al., 2009; Stepan et al., 2015a). Additionally, there is a previously unknown
trisynaptic circuit. A subpopulation of DG granule cells target CA2 pyramidal neurons,
which synapse on distinct CA1 counterparts. But, its function and mode of operation
have yet to be clarified (Kohara et al., 2014; Stepan et al., 2015a). Beside the connectivity
pattern described above, different subregions of the HIP are connected with subcortical
structures including the amygdala, the hypothalamus, the medial septum, the raphe nu-
cleus, and the locus coeruleus. Furthermore, the HIP has a substantial commissural input
from the contralateral HIP and an ipsilateral associational loop (Nicoll and Schmitz, 2005;
Andersen et al., 2006; Stepan et al., 2015a). Complicating the picture, the HIP also in-
cludes associational loops and partly complex interneuronal circuits which mediate feed-
forward and/or feedback inhibition of principal neurons and disinhibition processes
(Klausberger and Somogyi, 2008; Stepan et al., 2015a).
The gross anatomy of the HF and associated structures has important functional impli-
cations. Out of several parallel pathways, the trisynaptic circuit (EC layer II (PP)! DG
! CA3 ! CA1 output subfield), with its prominent appearance and principally unidi-
rectional connectivity, is ideally suited to monitor polysynaptic activity flow within the
mammalian central nervous system.
1.3 Foundations of voltage-sensitive-dyes
Significant advances in neuroscience research have traditionally been intimately linked
to progress in methodological approaches to probe the complex function of the ner-
vous systems in various species including humans (Neher and Sakmann, 1976; Klar and
Hell, 1999; Zemelman et al., 2002). For functional analysis of the nervous system mod-
ern neuroscience offers various excellent techniques ranging from single-cell and local
field potential recording to more indirect analysis of whole brain activity using func-
tional magnetic resonance tomography (Neher and Sakmann, 1976; Andersen et al., 2006;
deCharms, 2008; Stepan et al., 2015a). But, to study assemblies of neurons during infor-
mation processing, these approaches are limited either by their spatial scale, because
recordings from individual or a few neurons ("microscale") typically provide little infor-
mation about the associated network, or by the facts that (1) non-invasive imaging meth-
ods ("macroscale") measure a surrogate signal whose spatial and temporal resolution is
subject to both physical and biological constraints, and (2) widely used analysis software
produce a high rate of false-positive results (Logothetis, 2008; Lewis and Lazar, 2013;
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Stepan et al., 2015a; Eklund et al., 2016). To provide a better understanding of brain
function, circuit-centered approaches which operate at the interface of the aforemen-
tioned methods are highly recommended (Karayiorgou et al., 2012; Lewis and Lazar,
2013; Stepan et al., 2015a). To directly study how neurons communicate across multiple
synapses in large/mesoscale networks in real time, high-speed optical techniques like
voltage-sensitive-dye imaging (VSDI) seem to be prerequisite to cover the methodolog-
ically demanding "mesoscale" of neuroscience research (Iijima et al., 1996; Airan et al.,
2007; Refojo et al., 2011; Stepan et al., 2012; Avrabos et al., 2013; Stepan et al., 2015a;
Stepan et al., 2015b).
Results
Design and Synthesis of VF Sensors. Our initial voltage sensors in-
corporate dichlorosulfoﬂuorescein as a membrane-impermeant
ﬂuorophore, a p-phenylenevinylene (PPV) molecular wire, and N,
N-dimethyl- or dibutylaniline as an electron-rich quencher
(Scheme 2). VF1.4.Cl comprises 2,7-dichlorosulfoﬂuorescein con-
nected via one vinylene unit to dibutylaniline (hence VF1.4.Cl).
VF2.4.Cl adds a second PPV unit, and VF2.1.Cl features the same
conﬁguration, with methyl substituted in place of butyl groups.
Correct positioning of the ﬂuorophore-wire donor within the
membrane is vital to take advantage of the vectoral nature of the
transmembrane electric ﬁeld and electron transfer. First, the lon-
gitudinal axis of the molecular wire must be normal to the plane
of the plasma membrane, to sample the full electric ﬁeld. Second,
dye molecules must all align in the same direction to avoid can-
celing out the electron transfer effect. Positioning the ﬂuorophore
at the extracellular leaﬂet of the membrane ensures ﬂuorescence
brightening upon depolarization; the opposite orientation of PeT
would give ﬂuorescence quenching upon depolarization.
The negatively charged sulfoﬂuorescein will preclude dye in-
ternalization and force an orientation in which the ﬂuorophore
adsorbs to the outer leaﬂet of the plasma membrane, with the
lipophilic molecular wire and alkyl aniline dangling into the lipid
bilayer. As an intervening spacer, PPV molecular wires are an
ideal choice because of their low attenuation values (26), synthetic
tractability, and demonstrated ability to conduct current through
lipid bilayers (31). Anilines are common PeT donors and the di-
alkyl groups should enhance uptake into the plasma membrane.
A modular synthetic design both allows for rapid generation of
the voltage sensors and enables future derivatization (Scheme 2
and SI Appendix). Coupling of the molecular wire styrene unit 1,
available in one step from 4-di-butylaminobenzaldehyde, with
iodo-functionalized dichlorosulfoﬂuorescein 2 via a Pd-catalyzed
Heck reaction gives VF1.4.Cl in good yield. An analogous re-
action with molecular wire 3, available in two steps from 1, gives
VF2.4.Cl in 70% yield. A parallel reaction beginning from styrene
4 furnishes VF2.1.Cl in good yield. All dyes feature emission and
excitation proﬁles typical of dichloroﬂuoresceins (VF1.4.Cl: λmax =
521 nm, ε = 93,000 M−1·cm−1, λem = 534 nm, Φ = 0.24; VF2.4.Cl:
Scheme 1. Mechanisms of ﬂuorescent voltage sensing. (A) Electrochromic VSDs sense voltage through the Stark effect, whereby the chromophore interacts
directly with the electric ﬁeld. Absorption of a photon signiﬁcantly alters the excited state molecular dipole, which at hyperpolarizing potentials is stabilized
(Left). At depolarizing potentials the charge shift inverted state is destabilized (Right). Changes in the energy levels of the chromophore result in small
spectral shifts in the emission of the dye. (B) FRET-pair voltage sensors use lipophilic anions (red), which partition in a voltage-dependent fashion on the inner
or outer leaﬂet of the membrane. Depolarization causes translocation of the anion, which can now quench the ﬂuorescence of an immobilized ﬂuorophore
(green). (C) Molecular wire PeT VSDs depend upon the voltage-sensitive electron transfer from an electron-rich donor (orange) through a membrane-
spanning molecular wire (black) to a ﬂuorescent reporter (green). At hyperpolarizing potentials, the electric ﬁeld is aligned antiparallel to the direction of
electron transfer, resulting in efﬁcient PeT and quenched ﬂuorescence (Left). Depolarization aligns the electric ﬁeld in the direction of PeT, decreasing the
rate of electron transfer and increasing ﬂuorescence (Right).
Scheme 2. Synthesis of VF probes.
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Fig. 1.3. Physical mechanism of electrochromism.
Absorption of a photon significantly alters the charge
distribution of the chromophore (strong induced
dipole, excited state). Membrane potential changes
(neuronal activity) influence the relative energy of the
ground and excited states of the chromophore (hyper-
polarization= stabilized, depolarization= the charge
shift inverted state is destabilized), resulting in spec-
tral shifts in the emission of the dye (adapted from
Miller et al., 2012).
VSDI employs organic membrane-bound
molecules. Their optical properties are
often mediated by fluorescence or ab-
sorption, and various dye-specific molec-
ular mechanisms that account for a
(membrane) potential-dependent change
of their optical properties have been de-
scribed so far. These dyes in combination
with advanced optics allow the analysis of
neuronal activity on a millisecond scale,
with micrometer-range spatial resolution
and a scope spanning the entire brain
circuits under investigation (Tominaga et
al., 2000; Grinvald and Hildesheim, 2004;
Airan et al., 2007; Carlson and Cou ter,
2008; Chemla and Chavane, 2010; Stepan
et al., 2012; Stepan et al., 2015b). Peterka
et al. (2011) emphasize that voltage-imaging might be the most appropriate tech ique f r
a complete description of the activity of neurons or of their subcellular compartments
(Peterka et al., 2011). But, significant technical challenges associated with the biophysical
constraints of the measurements themselves, might account for the more frequent use
of alternative methods (e.g. calcium-imaging; Peterka et al., 2011). Biophysical mecha-
nisms leading to voltage sensitivity in plasma membrane measurements include among
others, repartitioning, reorientation, electrochromism or fluorescence resonance energy
transfer (FRET) (Bak r et al., 2005; Peterka et al., 2011; Mill r et al., 2012). The dye used
here, Di-4-ANEPPS, is a f st fluorescent styryl- dye that stably inserts into cytoplasmic
membranes and is thought to sense changes in the surrounding electrical field via elec-
trochromism. This is enabled by the core of Di-4-ANEPPS, a chromophore with large
differences in its dipole moment that directly interacts with light (Fluh er et al., 1985;
Peterka et al., 2011). Upon absorption of light the chromophore changes its electronic
structu e and moves from its ground state to its low-lying electronically excited state
accompanied by a large intern l charge transfer and large induced dipoles (Figure 1.3).
These states are differentially stabilized by depolarizing and hyperpolarizing membrane
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potentials, which changes the energy levels of the chromophore resulting in small spec-
tral shifts in the emission of the dye (Canepari and Zecevic, 2010; Peterka et al., 2011;
Miller et al., 2012). Di-4-ANEPPS’s emission spectrum is shifted to longer (excited state
molecular dipole is stabilized = hyperpolarization) or shorter (the charge shift inverted
state is destabilized = depolarization) wavelengths (Figures 3.2 B; 1.3; Peterka et al., 2011;
Miller et al., 2012; Stepan, 2015). This mechanism allows to differentiate between ex-
cited and/or unexcited tissue and to calculate the fractional change of fluorescence (%
4F/F) for each pixel thus, reflecting a direct measurement of neuronal population ac-
tivity (Canepari and Zecevic, 2010; Loew, 1992; Miller et al., 2012; Tominaga et al., 2000;
Stepan, 2015). Because the electric field and the energy levels of the fluorophore directly
interact, the kinetics of voltage sensing occur on a timescale commensurate with absorp-
tion and emission, resulting in ultrafast spectral emission shifts (fs to ps), many orders
of magnitude faster than required to resolve action potentials (ms) in neurons (Miller et
al., 2012; Stepan, 2015). Importantly, the magnitude of the wavelength shift is linearly
related to the size of the change in potential resulting in a direct, fast, and linear mea-
sure of the change in membrane potential. Values for changes of 4F in neuronal tissue
stained with Di-4-ANEPPS typically range around 10% per 100 mV (Fluhler et al., 1985;
Baker et al., 2005; Stepan, 2015).
Chapter 2
Aims of the thesis
Comprehensive research in various species, including humans, has shown that the hip-
pocampus (HIP) plays a central role in stress-related psychiatric disorders (SRPDs) and
provided substantial evidence that disease symptoms partly result from malfunction
of information processing within the hippocampal network (Castrén, 2005; Ressler and
Mayberg, 2007; Singewald et al., 2015; Pertwee, 2015). Furthermore, the endocannabi-
noid system (ECS), which is highly expressed in the HIP, seems to be dysregulated in SR-
PDs, providing a potential target for pharmacological intervention (Micale et al., 2013).
Whereas classical electrophysiology shed light on the function of single cells and small
neuronal populations these methods however, provide a limited and possibly distorted
picture of how large/meso-scale neuronal networks respond to pharmacological inter-
vention in real time (Lewis and Lazar, 2013). In recent years methods like optogenetics,
calcium-imaging, voltage-sensitive-dye imaging (VSDI) or their combination ("all opti-
cal") provide more circuit-centered approaches for the analysis of disease related neu-
ronal network activity (Karayiorgou et al., 2012; Emiliani et al., 2015). Within this frame-
work, the present dissertation intended to address two major questions:
1. First, does a commonly used drug to treat the symptoms of SRPDs (diazepam) and
an endocannabinoid system-enhancer (AM404), modulate neuronal network dy-
namics in the HIP?
2. Second, which receptor(s) mediate(s) putative effect(s) of AM404 on neuronal net-
work dynamics in the HIP?
To address these questions VSDI was applied to mouse brain slices. VSDI allows the
analysis of neuronal activity on a millisecond time-scale, with a micrometer-range spatial
resolution and, most notably, a scope spanning the entire HIP (Airan et al., 2007; Peterka
et al., 2011; Stepan et al., 2012; Stepan et al., 2015a).
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Chapter 3
Material and Methods
3.1 Animals
Male C57BL/6N mice were purchased from the MPI of Biochemistry (Martinsried, Ger-
many) at an age of 8-12weeks. Male conditional dopamine 1 receptor (D1R)-CB1R-/- mice
(mice lacking CB1Rs on D1R-expressing neurons in the forebrain, D1R-CB1R-knockout
(KO) and their respective wild-type (WT) littermate controls (D1R-CB1R+/+, D1R-CB1R-
WT) were provided by Carsten T. Wotjak, and tested at an age of 12-16 weeks. In brief,
conditional D1R-CB1R-KO mice were generated by crossing a mouse line in which the
CB1 coding region is flanked by two loxP sites (CB1-floxed mice, CB1f/f), with a trans-
genic mouse line where Cre recombinase is expressed under the control of the regulatory
sequences of a cell type specific promotor, here, of the dopamine receptor D1 (D1-Cre;
Marsicano et al., 2003; Monory et al., 2007). In these mice the CB1 receptor is deleted in
all D1 receptor expressing neurons of the forebrain but maintains its expression in the
rest of the brain. All animals were housed one to five per standard cage (25 x 19 cm) at
the animal facility of the Max Planck Insitute of Psychiatry (MPIP) in Munich. The ani-
mals received food and water ad libitum and temperature and humidity were maintained
constant (22  C ± 1  C; relative humidity 55% ± 10%) with a 12 h light/dark cycle (lights
on from 7:00 A.M. to 7:00 P.M.). All experimental procedures were approved by the Com-
mittee of Animal Health and Care of the local governmental body and were performed
in strict compliance with the guidelines for the care and use of laboratory animals set by
the European Community.
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3.2 Preparation and staining of brain slices
Mice were anesthetized with isoflurane (see Appendix 7.1) and decapitated at the level of
the cervical spinal cord using an animal guillotine. All following steps were done in ice-
cold homogenizated and partially frozen sucrose-based saline (Bischofberger et al., 2006).
The saline (pH 7.4) was saturated with carbogen gas (95% O2/5% CO2) and consisted of
(in mM): 87 NaCl, 2.5 KCl, 25 NaHCO3, 1.25 NaH2PO4, 0.5 CaCl2, 7 MgCl2, 25 glucose,
and 75 sucrose. After decapitation, the head was transferred into a petri dish and the
brain was rapidly removed from the cranial cavity. Next, the brain was separated into its
hemispheres. The right hemisphere was prepared for the slicing procedure by a special
transversal cut, which is sometimes called "magic cut", to maintain the intrahippocam-
pal axonal projections as good as possible (Bischofberger et al., 2006). Next, the brain was
gluedwith the "magic cut" side on a cooled tissue block with a tissue adhesive made from
enbucrilate (Histoacryl R ; Aesculap AG; Tuttlingen; Germany). Then the tissue block was
immediately placed into the cutting chamber of a vibratome (HM650V, Freq.: 66, Ampl.:
0.9, V=8; Thermo Scientific; Waltham; United States of America (USA)). Subsequently, 350
µm-thick horizontal slices containing the HIP were cut with a cleaned (acetone, ethanol)
razor blade (Dreaming; Goldhand mbH; Düsseldorf; Germany) and transferred into a
maintenance chamber. According to Bischofberger et al. (2006), the angle between blade
and horizontal plane was set at ⇠ 17  . After preparation, slices were incubated in car-
bogenated sucrose-based saline for at least 30 min at 34  C. Subsequent staining of brain
slices with the voltage-sensitive dye Di-4-ANEPPS (see 7.1; Tominaga et al., 2000; Airan
et al., 2007; Refojo et al., 2011; Stepan et al., 2012; von Wolff et al., 2011, dissolved in
dimethyl sulfoxide (DMSO) to a 20.8 mM stock solution) was carried out at room tem-
perature (23  25  C). For staining, slices were kept for 15 min in carbogenated phys-
iological saline containing Di-4-ANEPPS (7.5 g/ml; <0.1% DMSO; Refojo et al., 2011;
von Wolff et al., 2011). The physiological saline (pH 7.4) consisted of (in mM): 125 NaCl,
2.5 KCl, 25 NaHCO3, 1.25 NaH2PO4, 2 CaCl2, 1 MgCl2, and 25 glucose. Afterwards, slices
were transferred back to the maintenance chamber and stored at room temperature for a
minimum of 30 min in Di-4-ANEPPS-free, but bicuculline methiodide (BIM)-containing
(0.6 µM, for rationale see (Stepan et al., 2012)) carbogenated physiological saline.
3.3 Brain slice experiments
VSDIwas conducted at room temperature on a vibration-cushioned table (TMC; Peabody;
USA), equipped with a Faraday cage (TMC; Peabody; USA) to minimize extraneous elec-
trical noise. In a submerged-type recording chamber, slices were fixed with a custom
made platinum frame/nylon string harp ("grid") and continuously superfused with BIM
(0.6 µM), containing carbogenated physiological saline (4-5 ml/min flow rate). The cir-
culation was established by using a combination of a gravity system (for influx) and a
peristaltic pump (Ismatec; Glattburg; Germany; for outflow). Thus, vibrations at the
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surface of the superfusion medium were reduced. These settings avoid motion arti-
facts which is paramount for optical recordings. Figure (3.1A) depicts one representa-
tive slice that was cut at a distance between 2.3 and 3.0 mm (± 0.1 mm) from the ven-
tral base of the brain. Previous research revealed that hippocampal trisynaptic circuit
(HTC)-Waves can be most reliably evoked in these particular slices (Stepan et al., 2012;
Stepan et al., 2015b). According to the "ventral/dorsal HIP hypothesis" (see 1.2; Maggio
and Segal, 2007; Fanselow and Dong, 2010), experiments were conducted in the dorsal
HIP or in the intermediate zone. EC/DG-input was evoked by patterned electrical stim-
B 
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Scalpel blade cut 
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DG 
CA3 
Glass pipette Blade 
1 cm 
500 µm 
Fig. 3.1. Deafferentiations in hippocampal brain slices. (A) Illustration of deafferentiations performed
with a scalpel blade and the microknife in hippocampal brain slices. (B) Custom made microknife used for
cutting direct cortical inputs to areas CA3 and CA1 (A, modified from Stepan et al., 2012, B, adapted from
Stepan, 2015).
ulation of the PP, which also contains EC layer II projections which travel in the ML of
the DG and directly innervate distal apical dendrites of CA2 and CA3 pyramidal neu-
rons (Kohara et al., 2014). After fixation of the slice, but before placing stimulation or
recording electrodes, these fibers were cut at the tip of the suprapyramidal blade, the
point where they exit the DG (Andersen et al., 2006, Figure 3.1A). Temporoammonic (EC
layer III) projections that directly innervate the most apical dendrites of CA1 pyramidal
neurons were likewise functionally inactivated by a cut, ranging from the hippocampal
fissure to the cortical surface (Figure 3.1A, Andersen et al., 2006). The deafferentiations
were accomplished by a tapered scalpel blade and a custom-made "microknife" (approx-
imately 100 µm blade length; Figure 3.1A,B; Stepan et al., 2012).
3.4 Voltage-sensitive dye imaging (VSDI)
VSDI and data analysis were performed using the MiCAM02 hard- and software pack-
age (BrainVision; SciMedia Ltd.; Costa Mesa; USA). The tandem-lens fluorescence mi-
croscope was equipped with the MiCAM02-HR camera (charged coupled device (CCD)
camera) and a 2x and 1x lens at the objective and condensing side, respectively (Figure
3.2A).
By a halogen light source (MHAB; 150W; Moritex Corp.; Tokyo; Japan), an excitation fil-
ter (530 nm pass) and a dichroic mirror (520 ⇠ 560 nm reflect (>90%), 600 nm (>85%)
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Fig. 3.2. Voltage-sensitive dye imaging setup. (A) Components used for imaging of neuronal activities via
fluorescence emitted from voltage-sensitive dyes, recorded with a CCD camera. (B) Electrochromic voltage-
sensitive dyes are believed to sense a change in the surrounding electric field via electrochromism or the
molecular stark effect. Upon depolarization, the emission spectrum of Di-4-ANEPPS shifts to shorter wave-
lengths with a concomitant decrease of the area under the curve (4F) of integrated wavelengths > 590 nm.
(A, adapted from Stepan, 2015), B, modified from Canepari and Zecevic, 2010, p.16). Abbreviations: 4F,
change in fluorescence; Vm, membrane voltage; VSD, voltage-sensitive dye.
pass), the light with was reflected towards the objective lens to illuminate the brain slice,
stained with Di-4-ANEPPS. Subsequently, the fluorophore Di-4-ANEPPS emits photons
(fluorescence) that were collected and projected onto the CCD sensor through an emis-
sion filter (> 590nm; Figure 3.2A; Tominaga et al., 2000). Unless noted otherwise, stan-
dard settings of the MiCAM02-HR camera system were as follows: 88 x 60 pixels frame
size, 36.4 x 40.0 µm pixel size, and 2.2 ms sampling time.
3.5 Processing and quantification of VSDI data
From recorded VSDI signals, %4F/F for wavelengths > 590 nm was calculated (Figure
3.2B). For all quantifications, % 4F/F values were spatially and temporally smoothed,
using a 3 x 3 x 3 average filter. VSDI signals presented in images were smoothed with a
5 x 5 x 3 average filter. To attenuate slow signal components produced from bleaching
of the voltage-sensitive dye (Carlson and Coulter, 2008) and a slight summation of 5 Hz
neuronal responses, a weak high-pass filter of the MiCAM02 software was applied (t=
220 ms) to the imaging data afterwards. Pixelation of images was reduced by the interpo-
lation function of the MiCAM02 software. For analysis of neuronal population activity
in hippocampal subregions, three standardized region of interest (ROI) were manually
set according to anatomical landmarks. The circular CA3-ROI (r = 4 pixels) was placed
into the CA3 region close to the DG, but not overlapping with it. The circular CA1-ROI
(r = 4 pixels) was positioned into the CA1 subfield at a distance of ⇠ 200 µm from the
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visually identified distal end of the stratum lucidum. The CA3-, and CA1-ROI spanned
the stratum oriens, stratum pyramidale, and stratum lucidum/radiatum (Figure 4.2A).
0
0.1
0.3
0.5
0.7
0 100 200 300 400
0.1
0.3
0.5
Time (ms)
F D
S  
p e
a k
a m
p l
i t u
d e
( %
 Δ
F /
F )
FDS peak amplitude
107.8 110
before
stimulus
Stimulus onset
Fig. 3.3. Quantification of VSDI signals. To quan-
tify FDSs, the value (% 4F/F) before stimulus onset
(107.8 ms) was subtracted from the value at FDS peak
amplitude (adapted from Stepan, 2015).
The polygon DG-ROI (composed of ⇠ 450
pixels) enclosed the outer two layers of the
DG (without the hilus) and was created by
the polygon-drawing function of the Mi-
CAM02 software (Figure 4.2A). The aver-
age of smoothed % 4F/F values within a
particular ROI served as a measure of neu-
ronal population activity. For further anal-
ysis in BrainVision, the peak amplitude
of the fast depolarization-mediated signal
(FDS) was corrected (Figure 3.3), to avoid
that background fluorescence (noise) bi-
ased FDS values during pharmacological
experiments. As a final measure of neu-
ronal activities the last FDS in area CA3
and CA1, and the the first FDS in the DG were used (Figure 4.2B). From all data pre-
sented in absolute values (only for illustration of results) the peak amplitude was calcu-
lated in Excel (Version 2003; Microsoft; Redmond; USA) without applying the correction
procedure.
3.6 Electrical stimulation techniques
In all experiments, neuronal activity was evoked by square pulse electrical stimuli (200
µs pulse width), delivered through custom-mademonopolar tungsten electrodes (Teflon-
insulated to the tip of 50 µmdiameter). These electrodes enabled a precise placement into
the neuronal tissue at the stimulation site and do not interfere with the imaging process
(e.g., by producing irritating shadows as observed with other electrodes). A highly lo-
calized electrical stimulation was achieved by placing the indifferent electrode far away
from the slice in the recording chamber. The electrode used for evocation of EC/DG-
input was placed under a binocular on the visually identified PP at distance of 40 µm (±
10 µm) away from its entry zone into the DG, to avoid direct stimulation of neurons and
their dendrites within the ML (Figure 4.2A).
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3.7 Chemicals
All salts for the physiological saline solutions were purchased from Sigma-Aldrich. For
preparation of stock solutions, AM404 and diazepamwere dissolved in DMSO. For phar-
macological experiments the corresponding amount of stock solution was diluted in ar-
tificial cerebrospinal fluid (ACSF). Therefore, DMSO was present at a maximum concen-
tration of  0.025% (AM404) and  0.02% (diazepam). The corresponding amount of
DMSO was added during baseline recordings. For a summary see Table (7.1).
3.8 Statistics
Statistical significance was assessed by paired- and unpaired t-tests when appropriate.
All tests were run in SigmaStat 3.5 (Systat Software; Chicago; USA) and differences were
considered significant if p < 0.05. Data are given as mean ± s.e.m.
Chapter 4
Results
This work is a further implementation of a recently developed voltage-sensitive dye
imaging (VSDI) assay in mouse brain slices (see Material and Methods 3; Stepan et al.,
2012; Stepan et al., 2015b). This high-speed optical approach allows real-time recording
of activity patterns in large/meso-scale neuronal networks and here, in particular, the
investigation of activity waves across the entire hippocampal trisynaptic circuit ("HTC-
Waves"; Figures 4.1; 4.3; Stepan et al., 2012; Stepan et al., 2015b).
DG 
DG-ROI 
CA1-ROI 
TP 
MF 
CA1 
CA3 
SC 
CA3-ROI 
HTC 
VSDI 
Stim 
TA 
PP 
! Deafferentation 
 
Fig. 4.1. Experimental setup for recordings of polysynaptic activity flow through the HTC network. Ar-
rangement used for experiments shown in Figures (4.3 - 4.8). Abbreviations: MF, mossy fiber; PP, per-
forant path; ROI, region of interest; SC, Schaffer collateral; Stim, extracellular electrical stimulation; TA,
temporoammonic pathway (adapted from Stepan et al., 2015b).
HTC-Waves were triggered by theta-frequency stimulation trains of perforant path fibers
(PP), in the following EC/DG-input, mimicking synchronous theta-rhythmical spiking
of entorhinal cortex (EC) layer II neurons (Mizuseki et al., 2009; Quilichini et al., 2010;
Burgalossi et al., 2011; Stepan et al., 2012; Stepan et al., 2015b). Such activity in the
entorhinal-hippocampal system is physiologically highly relevant, because of its major
role in complex cognitive functions in mammals, including episodic and spatial memory
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(Buzsàki, 2002; Hafting et al., 2005; Rutishauser et al., 2010). Moreover, EC/DG-input in
the theta range most effectively passes filter mechanisms associated with the hippocam-
pal trisynaptic circuit (HTC; Stepan et al., 2012; Stepan et al., 2015a). PP-fibers synapse
on dendrites of DG principle cells (granule cells) which subsequently give rise to mossy-
fibers, the anatomically most prominent non-commissural/associational innervation of
CA3 pyramidal cells. To study "pure" activity propagations through the downstream
HTC-network, PP fibers that directly innervate areas CA3, CA2 and CA1 (Watson et
al., 2011; Kohara et al., 2014), were micro-dissected via specific cuts in all experiments
(Figures 3.1, 4.1, 4.2A). As VSDI measure of neuronal activity, "regions of interest" (ROI)-
extracted fast, depolarization-mediated imaging signals (FDSs) were used (Figures 4.1,
4.2A, 4.3; Tominaga et al., 2000; Airan et al., 2007; Refojo et al., 2011; Stepan et al., 2012).
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0.2% ΔF/F 
1st FDS 
Last  
FDS 
5 Hz-Stim 
Fig. 4.2. Anatomical position of ROIs and experimental protocol. (A) Illustration of ROI positions
and deafferentiations in relation to important landmarks in the HIP. (B) Depiction of ROI-extracted fast,
depolarization-mediated imaging signals (FDSs), which reflect a compound signal from all stained neuronal
membranes, but mainly derive from neuronal action potentials and glutamatergic excitatory postsynaptic
potentials (EPSPs). Note the typically increasing CA3 signals and the delayed occurrence of CA1-FDSs,
which predominantly result from frequency facilitation of neurotransmission at mossy fiber synapses onto
CA3 pyramidal neurons (Nicoll and Schmitz, 2005). Abbreviations: SL, stratum lucidum; SR, stratum radia-
tum.
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Fig. 4.3. Hippocampal activities in response to 5 Hz EC/DG-input. VSDI filmstrip of a submaximal HTC-
Wave evoked by theta-frequency (5 Hz) electrical stimulation train of the PP (stimulus 7). Only selected
imaging frames are shown (sampling time was 2.2 ms). Warmer colors represent higher values of the frac-
tional change in fluorescence (4F/F) of the voltage-sensitive dye and, thus, stronger neuronal activity.
4.1 Opposing effects of diazepam and AM404 on HTC-Waves
Previous results show that HTC-Waves provide a valuable assay for studying drug ef-
fects on polysynaptic activity flow through the classical input/output circuit of the HIP
(Stepan et al., 2012; Stepan et al., 2015b). Consistently, theta-frequency stimulus trains
applied to the PP containing 7 pulses every 2 min, were suited to conduct stable baseline
recordings of HTC-Waves (Figures 4.2, 4.4; Stepan et al., 2015b). The number of stimuli
was held constant within an experiment and as a final measure of DG, CA3, and CA1 ac-
tivity levels, the mean of FDS out of three consecutive acquisitions was used and paired
t-tests were employed to determine differences of FDSs at minutes 0 to 18 vs. minutes
42 to 60. Electrical stimulation intensity was set (15-35 V), to obtain CA1-FDS ranging
within 0.1 to 0.3 % 4F/F (Stepan et al., 2015b). Applying these settings, control experi-
ments with DMSO (solvent of diazepam and AM404) revealed a slight decrease of FDS
amplitudes in all hippocampal subregions (significant in the DG; Figure 4.4). To avoid
underestimation (AM404) or overestimation (diazepam) of drug effects the correspond-
ing percentage of decrease (DG, -5.6 ± 1 %; CA3, -5.5 ± 2 %; CA1, -5.5 ± 2 %) was added
in subsequent experiments.
Benzodiazepines (BDZs) like diazepam are widely used for acute symptom relieve in
patients suffering from SRPDs, but simultaneously impair cognitive function in humans
and animals, partly, due to their potentiating effect on GABAA receptor function in the
HIP (Shimizu et al., 1998; Chouinard, 2004). In line with this, and, consistent with previ-
ous data (Stepan et al., 2012), bath applied diazepam rapidly decreased DG-, CA3-, and
CA1-FDSs (Figure 4.5).
Substantial evidence has accumulated, implicating the endocannabinoid system (ECS) to
be involved in the pathophysiology of SRPDs and all its components are highly expressed
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Fig. 4.4. DMSO effect on HTC-Waves. DMSO (0.025%) decreases FDSs in the DG (t(7) = -5.4, p = 0.001,
paired t-test), but has no significant effect in areas CA3 and CA1 (n = 8 slices/4 mice). ??p < 0.01.
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Fig. 4.5. Diazepam effect on HTC-Waves. Diazepam (1µM) rapidly decreases FDSs in the DG (t(5) = -6.6, p
= 0.001, paired t-test) and areas CA3 (t(5) = 5.0, p = 0.004, paired t-test) and CA1 (t(5) = -8,6, p < 0.001; paired
t-test) (n = 6 slices/5 mice). ??p < 0.01, ???p < 0.001.
by excitatory and inhibitory neurons in the HIP (Marsicano and Lutz, 1999; Micale et al.,
2013). Moreover previous research found anxiolytic- and antidepressant effects of ECS-
modulators in rodents, which was associated with less pronounced impairment, or even
enhanced amnestic functions (Mangieri and Piomelli, 2007; Riebe et al., 2012; Micale et
al., 2017). In line with that, and in contrast to diazepam, the endocannabinoid (eCB)
reuptake inhibitor/degradation blocker AM404 (Beltramo et al., 1997) rapidly amplified
CA3-, and CA1-FDSs (Figure 4.6).
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Fig. 4.6. AM404 effect on HTC-Waves. AM404 (10µM) rapidly amplifies FDSs in areas CA3 (t(7) = 3.6, p =
0.009, paired t-test) and CA1 (t(7) = 3,5, p = 0.010, paired t-test), but not in the DG (n = 8 slices/8 mice). ?p <
0.05, ??p < 0.01.
4.2 AM404 effects are mediated by D1R positive neurons
There is potentially a wide range of cellular mechanisms underlying the enhancing ef-
fects of AM404 on HTC-Waves. AM404 facilitates eCB signaling and is a potent activa-
tor (full agonist) of TRPV1 channels (Beltramo et al., 1997; Beltramo and Piomelli, 2000;
De Petrocellis et al., 2000; Zygmunt et al., 2000; Pertwee, 2015). Pilot-experiments us-
ing the CB1R antagonist/inverse agonist rimonabant (SR141716) and the TRPV1 antag-
onist SB363791 revealed that these substances exert strong effects on hippocampal net-
work activity, which somehow hampered a more detailed pharmacological dissection
of AM404 effects. Experiments with conditional CB1R-KO mice lacking CB1Rs on fore-
brain GABAergic, glutamatergic and dopamineric neurons support the hypothesis that
different neuronal subpopulations might be involved in the cellular, molecular and be-
havioral effects of eCB and ECS-modulators (Marsicano et al., 2003; Monory et al., 2007;
Haring et al., 2012; Llorente-Berzal et al., 2015). More specifically, recently obtained
data suggest CB1Rs on D1R positive neurons to be critically involved in HIP-dependent
AM404 effects on specific learning tasks (Micale et al., 2017). Therefore, AM404 was
tested in mice lacking CB1Rs on D1R receptor containing neurons (D1R-CB1R-KO) and
control littermates (D1R-CB1R-WT). Bath application of AM404 to slices fromD1R-CB1R-
KOmice had no effect onDG-, CA3-, and CA1-FDSs, while AM404 again rapidly elevated
HTC-Waves in D1R-CB1R-WT mice (Figure 4.7). This shows that CB1R expression on
D1R receptor positive forebrain neurons is essential for AM404 effects on hippocampal
network activity.
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Fig. 4.7. CB1Rs on D1R positive neurons mediate AM404 effects. (A, B) AM404 (10µM) effects are present
in D1R-CB1R-WT mice ( (A) DG: t(5) = 4.3, p = 0.008; CA3: t(5) = 4.7, p = 0.005; CA1: t(5) = 11,4, p < 0.001;
paired t-tests; n= 6 slices/6 mice), but not in CB1R-D1R-KO mice, except for the DG ((B) DG: t(5) = 2.8, p =
0.032; paired t-test; n= 7 slices/7mice). ?p < 0.05, ??p < 0.01, ???p < 0.001).
4.3 Hippocampal subregion specific drug effects
Next, it was tested if drug induced enhanced/weakened HTC-Waves result from in-
creased/ decreased neuronal activity in both, area CA3 and CA1. Further analysis of
the data revealed that the amplitude of CA1-FDSs linearly increased with the amplitude
of CA3-FDSs (data fromN= 4 DMSO experiments, Figure 4.8A). CA3/CA1 activity ratios
were calculated for all experiments to asses drug effects in CA subregions. These ratios
were calculated by dividing the mean amplitude value of the last three CA3-FDSs by the
mean amplitude value of the last three CA1-FDSs within a recording sequence (Stepan et
al., 2015b). AM404 reduced CA3/CA1 activity ratios in D1R-CB1R-WT animals but not
in C57BL/6Nmice mice while diazepam had the opposite effect (Figure 4.8B). No change
in CA3/CA1 activity ratios was found in DMSO experiments and in D1R-CB1R-KOmice
(Figure 4.8B). These findings suggest that drug effects on HTC-Waves originated in most
cases from impaired/enhanced neurotransmission in both, area CA3 and area CA1.
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Chapter 5
Discussion
The present data illustrates a dichotomy between the ability of diazepam, a widely pre-
scribed drug to treat the symptoms of SRPDs (Rudolph and Knoflach, 2011) and AM404,
an endocannabinoid signaling enhancerwith antidepressant and anxiolytic potential (Bel-
tramo et al., 1997; Adamczyk et al., 2008; Riebe et al., 2012), to modulate the activity flow
through the the HIP. Diazepam impaired activity propagations through the hippocam-
pal trisynaptic circuit (HTC-Waves) in the DG and in CA regions (Stepan et al., 2015b),
while AM404 caused an amplification of HTC-Waves in areas CA3 and CA1. The rapid
facilitation of HTC-Waves after AM404 application supports previous findings suggest-
ing a prominent role for the eCB system in the regulation of hippocampal homeostasis
and excitability (Marsicano et al., 2003; Péterfi et al., 2012; Stempel et al., 2016). This al-
tered excitability in a brain area ascribed a pivotal role in learning and memory and the
pathophysiology of SRPDs (Burgess et al., 2002; Berton and Nestler, 2006), in combina-
tionwith previous results, indicating that diazepam severely disrupts cognitive processes
while AM404 facilitates acquisition of new information (Buffett-Jerrott and Stewart, 2002;
Micale et al., 2017), further supports the hypothesis that drugs, which impact diverse
cellular- and molecular processes, change behavioral output by a common "circuit-level"
mechanism (Castrén, 2005; Airan et al., 2007; Stepan et al., 2015b). In line with that,
Stepan et al. (2015b) found that various antidepressants (ADs), belonging to different
chemical/functional classes, and drugs with antidepressant potential like brain-derived
neurotrophic factor (BDNF), ketamine and lithium enhance HTC-Waves at clinically rel-
evant concentrations, whereas substances with no antidepressant potential and stress
weaken HTC-Waves (Stepan et al., 2015b). Similar studies using VSDI to map diverse
drug-, or genetically induced cellular alterations, also found specific circuit-level en-
dophenotypes supporting the view that VSDI might be useful to narrow the gap be-
tween cellular/molecular processes and behavioral outcome (Airan et al., 2007; vonWolff
et al., 2011; Refojo et al., 2011; Kim et al., 2012; Avrabos et al., 2013; Ikrar et al., 2013;
Stepan et al., 2015b).
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Likemostmedications commonly used to treat SRPDs (e. g. ADs), AM404 has a polyphar-
macological profile causing multifarious molecular-, cellular-, and behavioral actions
by itself, including enhanced eCB-signaling (see Introduction 1.1; Beltramo et al., 1997;
De Petrocellis et al., 2000; Zygmunt et al., 2000; Glaser et al., 2003; Hogestatt et al., 2005;
Wiskerke et al., 2012; Kano, 2014; Pertwee, 2015; Micale et al., 2017; Busquets Garcia et al.,
2016). Substances affecting a variety of targets are sometimes called "dirty" or "promis-
cuous" drugs and were supposed to have a better efficacy (Frantz, 2005; Marks et al.,
2008), but delineating their exact mode of action has proven difficult (Moreira et al., 2012;
Busquets Garcia et al., 2016). AM404 elevates plasmatic levels of AEA either by reuptake
inhibition (Beltramo et al., 1997; Fu et al., 2012) and/or by blocking degradation enzymes
like FAAH-1 (Glaser et al., 2003; Fowler, 2013; Glaser et al., 2005). Moreover, AM404 ele-
vates 2-AG levels in the brain (Hajos et al., 2004). Pharmacokinetic differences between
AEA and 2-AG could influence AM404-mediated effects (Hill et al., 2009). AEA binds
with high affinity to CB1Rs with Ki values of approximately 50-1000 nM but is a par-
tial agonist resulting in poor efficacy. By contrast, 2-AG binds to CB1Rs with Ki values
of approximately 1-10 microM, but is a potent, full agonist inducing a robust activation
of downstream signaling cascades (Hill et al., 2009). Therefore, it was suggested that
AEA mediates tonic activation of CB1R receptors while 2-AG becomes activated during
activity-induced changes in synaptic transmission (Hill et al., 2009).
In general, the ECS predominantly functions by reducing neural excitability at GABAergic,
glutamatergic, serotonergic, dopaminergic, and cholinergic neurons through presynaptic
inhibition of transmitter release and by eCB-dependent forms of short- and long-term
depression via CB1Rs and CB2Rs (Kano, 2014; Morena et al., 2016; Stempel et al., 2016).
Therefore, it is conceivable that AM404 exerts a depressing effect on neurotransmission
and thus, HTC-Waves. However, distribution of CB1R is not equal across neuronal pop-
ulations in the HIP. GABAergic axon terminals express high levels of CB1Rs, especially
cholecystokinin (CCK) coexpressing interneurons, while expression levels in glutamater-
gic neurons are considerably low (Katona et al., 1999; Hu and Mackie, 2015; Pertwee,
2015). Because intrahippocampal information flow through glutamatergic synaptic trans-
mission is tightly regulated by GABAergic interneurons, their silencing could result in
disinhibition of local (Katona et al., 1999) and large/mesoscale neuronal networks Figure
(4.5). Moreover, AM404 and AEA are potent activators of TRPV1 (De Petrocellis et al.,
2000; Zygmunt et al., 2000), a non-selective cation channel, which mediates specific forms
of synaptic plasticity in the HIP (Marsch et al., 2007; Gibson et al., 2008), complemented
by numerous studies of eCB-driven modulation of neuronal excitability and plasticity
(Carta et al., 2014; Stempel et al., 2016). In conclusion, this underlines the importance of
high-speed optical approaches to leave extrapolation of cellular/molecular effects onto
network function, and to directly obtain pharmacological "net" effects in the mammalian
brain (Airan et al., 2007; Stepan et al., 2012; Avrabos et al., 2013; Stepan et al., 2015a;
Stepan et al., 2015b).
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The ECS is frequentlymentioned in connectionwith alterations of learning andmemory a
key symptom of SRPDs, which likely involves the HIP. But, how exactly are network pat-
terns in theHIP related to learning andmemory? HTC-Waves, triggered by 5Hz EC/DG-
input have been shown to induce high-frequency firing (>100 Hz) of CA3 pyramidal
neurons with subsequent induction of NMDA receptor-dependent CA1 long-term poten-
tiation (LTP) within a few seconds (Stepan et al., 2012). This neuroplastic phenomenon
is a compelling and extensively used experimental model for a cellular correlate that un-
derlies specific types of learning and memory, and the observation that CA1 LTP also
naturally occurs in the brain suggests that it is required for some forms of explicit learn-
ing in mammals (Gruart et al., 2006; Whitlock et al., 2006; Ho et al., 2011). Here, a reduced
number of stimuli was used which allows stable baseline recordings prevents the induc-
tion long-term synaptic changes (Stepan et al., 2012; Stepan et al., 2015b). But, weakened
activity propagations through the HTC should be less effective in the induction of CA1
LTP. Accordingly diazepam attenuates induction of CA1 LTP in vitro and in vivo most
likely via the BDZ site of GABAA-receptors resulting in potentiation of inhibitory neu-
rotransmission (del Cerro et al., 1992; Mori et al., 2001; Tokuda et al., 2010). Moreover,
extensive research in animals and humans suggest BDZ to impair HIP-dependent cog-
nitive abilities like the acquisition of reference and explicit memories (Timic et al., 2013;
Buffett-Jerrott and Stewart, 2002). This is of particular interest because drug administra-
tion in combination with psychotherapy represents the gold standard in the treatment
of many SRPDs (Association, 2013), which might be less effective when patients receive
BDZs (Guina et al., 2015). Interestingly, exposure of mice to chronic stress parallels the
effects of BDZ in the HIP (Stepan et al., 2015b). Chronic stress causes various molecular,
cellular and circuit changes in the HIP and alters the ECS throughout the brain (Sapol-
sky et al., 1986; Lutz et al., 2015). Although this clearly differentiates the mechanisms by
which stress and diazepam effect HTC-Waves, they share the ability to reduce cognitive
performance, which might involve a common endophenotype, namely, reduced activity
percolations through the HTC.
In contrast to diazepam, AM404 enhance HTC-Waves suggesting a lower threshold for
the induction of CA1 LTP and thus, facilitation of HIP-dependent memories. In line
with that, the AD fluoxetine, which also facilitates HTC-Waves, lowers the threshold for
LTP at a clinically relevant concentration (Stepan, 2015; Stepan et al., 2015b). On the
cellular level contradicting results were obtained regarding the ability of AM404, eCB
agonists and eCB to influence CA1 LTP induction (Terranova et al., 1995; Stella et al.,
1997; Abush and Akirav, 2010; Basavarajappa et al., 2014). Abush and Akirav (2010)
found that eCB agonists, including AM404 impaired CA1 LTP induction. Likewise re-
sults were obtained for the two most studied eCB AEA and 2-AG (Stella et al., 1997;
Terranova et al., 1995; Basavarajappa et al., 2014). However, it is important to note,
that most research on LTP in vitro is performed in isolated, monosynaptic pathways
and not on the network level with a physiological stimulation protocol (Buzsàki, 1988;
Abush and Akirav, 2010; Stepan et al., 2012). On the behavioral level, experiments us-
ing eCB or ECS modulators obtained different results depending on the applied drug,
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injection side and, most importantly, the test paradigm used (Abush and Akirav, 2010;
Riebe et al., 2012; Micale et al., 2017). Recently, Micale et al. (2017) found that learn-
ing about the safety of an environment (i.e., safety learning) allow mice to overcome
their avoidance behavior in a step-down avoidance task, a process that was impaired
by CA1 injections of diazepam and facilitated by CA1 injections of AM404 Micale et
al. (2017). Interestingly, AM404 effects were also absent in D1R-CB1R-KO mice, which
together with the present data suggests, that enhanced eCB signaling promotes safety
learning by facilitating activity propagation through the HTC (Micale et al., 2017). Fur-
thermore, the behavioral data support the hypothesis that cannabinoid agonists facil-
itate emotional memory like extinction of inhibitory avoidance, and impair nonemo-
tional memory like spatial navigation (Abush and Akirav, 2010). But, Abush and Aki-
rav (2010) and others emphasize that such simplified perspective underestimates the
complexity of how cannabinoids modulate memory processes (Abush and Akirav, 2010;
Lutz et al., 2015), supporting the present findings in the dorsal HIP, an anatomical part,
mainly involved in nonemotional processes (Fanselow and Dong, 2010).
Enhanced activity flow through the HTC and the associated increased output from area
CA1 in response to AM404 treatment, might not only be pivotal for cognitive processes
(Stepan et al., 2015a), but also represents a putative mechanism for the regulation of the
neuroendocrine stress response mediated by the hypothalamic-pituitary-adrenal (HPA)-
axis (Radley, 2012). HPA-axis dysfunction with hypersecretion of stress-hormones is
thought to be involved in the etiology of SRPDs and is found in up to 50% of depressed
patients (Holsboer, 2000; de Kloet et al., 2005). Especially the ventral HIP is part of a
multi-synaptic circuit, relevant for HPA-axis regulation an thus the amount of circulating
stress-hormones (Morena et al., 2016). A wealth of research shows that chronic stress
and elevated stress-hormones dampen HIP activity, causing a disruption of the HIP-
dependent negative feedback control over the HPA-axis (Watanabe et al., 1992; Radley,
2012), and likely promoting a vicious circle and further exacerbation of functional impair-
ment (Sapolsky et al., 1986). Excitatory hippocampal output has been shown to activate
inhibitory neurons in the bed nucleus of the stria terminalis which subsequently target
CRH-producing parvocellular neurons in the hypothalamus (Radley, 2012; Kondoh et
al., 2016). Accordingly, HPA-axis hyperactivity is dampened by ADs (Holsboer and Bar-
den, 1996), which share their circuit-level effect on HTC-Waves with AM404 (Stepan et
al., 2015b). Both enhance hippocampal output and thereby might counteract stress in-
duced impairment of hippocampal function and HPA-axis disinhibition (Radley, 2012;
Stepan et al., 2015b). This overlap in the effects of AM404 and ADs on hippocampal
network dynamics (Stepan et al., 2015b), in combination with the pronounced interac-
tions between stress and the eCB (Morena et al., 2016), supports the hypothesis that in-
creased eCB signaling might contribute to the mechanism by which ADs modulate HPA-
axis function (Hill et al., 2009). However, for reasons of methodology, HTC-Waves were
evoked in dorsal or intermediate parts of the HIP, so that future studies have to examine
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if the present results also apply for the ventral hippocampus (see also Introduction (1.2)).
Surprisingly, AM404 induced facilitation of HTC-Waves was absent in conditional D1R-
CB1R-KO mice. Expression of D1R has been shown in all hippocampal subregions (Gan-
garossa et al., 2012) and their activation modulates basic neurotransmission and synaptic
plasticity in brain slices (Otmakhova and Lisman, 1996; Kobayashi and Suzuki, 2007;
Ito and Schuman, 2007), as well as learning and memory in behaving animals (Sarinana
and Tonegawa, 2016). Although, coexpression of CB1Rs with D1Rs has not been shown
in the HIP so far (Hermann et al., 2002; Monory et al., 2007), the present results ascribe
D1R-CB1R coexpressing neurons a pivotal role in mediating network effects of AM404 in
the HIP. However, further studies combining anatomical, molecular, cellular and func-
tional methods will be necessary to clarify the existence and the functional properties of
D1R/CB1R coexpressing neurons in the HIP.
According to a recent study (Stepan et al., 2015b), a detailed analysis of the data revealed
that diazepam elevates the CA3/CA1 activity-ratio in the HIP, supporting the idea of
drug-related endophenotypes. The data also suggests drug effects in both, area CA3 and
area CA1, expressing high GABAA-receptor expression levels across the entire DG-CA-
axis (Rudolph and Knoflach, 2011). This is also true for AM404 (enhanced HTC-Waves
= reduced CA3/CA1 activity ratio; Stepan et al., 2015b). But, while the CA3/CA1 ac-
tivity ratio in D1R-CB1R-WT is reduced, it is unchanged in C57BL/6N animals (Figure
4.8). This discrepancy compared to a previous study (Stepan et al., 2015b), could result
from differences in age, genetic background, or from manifold methodological issues,
such as evoked neuronal activity levels, conservation of intrahippocampal connections
and vitality of the slice, all of which are pivotal for the induction of polysynaptic activity
flow (Bischofberger et al., 2006; Stepan et al., 2012). In contrast to previous work us-
ing the HTC-Wave assay (Stepan et al., 2012; Stepan et al., 2015b), activity levels in CA1
do not clearly exceed CA3 FDSs, which might account for missing effects of AM404 on
CA3/CA1 activity ratio in C57BL/6N mice.
In summary, VSDI was used to show how a complex pattern of drug induced cellu-
lar/molecular actions translate into a neuronal network response (Busquets Garcia et
al., 2016). The stereotyped effects of AM404 and diazepam, support the idea of shared,
circuit-level drug effects, to counteract disease-related dysfunction of the hippocampal
network (Stepan et al., 2015a; Stepan et al., 2015b). The HTC-Wave assay combined with
classical electrophysiology and cell type-specific silencing/activation of neuronal sub-
populations (optogenetics, "all optical approach"; Zhang et al., 2010; Emiliani et al., 2015),
should be used in future experiments to improve knowledge about ECS function and its
role in relevant neuronal network patterns like excitation/inhibition balance (Yizhar et
al., 2011).
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Chapter 7
Appendix
7.1 Chemicals
Tab. 7.1. Chemicals
SUBSTANCE CHEMICAL NAME SUPPLIER/CAT.NR. SOLVING
MEDIUM
ACSF SALTS - Sigma Aldrich/- Aqua dest.
AM404 N-(4-Hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide Tocris/1116 DMSO
1(S),9(R)-(-)-BICUCULLINE METHIODIDE [R-(R*,S*)]-5-(6,8-Dihydro-8-oxofuro[3,4-e]-1,3-benzodioxol-
6-yl)-5,6,7,8-tetrahydro-6,6-dimethyl-1,3-dioxolo[4,5-
g]isoquinolinium iodide
Sigma-Aldrich/14343 ACSF
DMSO Dimethyl sulfoxide Sigma-
Aldrich/PHR1309
-
DI-4-ANEPPS 4-(2-(6-(Dibutylamino)-2-naphthalenyl)ethenyl)-1-(3-
sulfopropyl)pyridinium hydroxide inner salt
Sigma-Aldrich/D8064 DMSO
DIAZEPAM 7-Chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one Sigma-Aldrich/D0899 DMSO
ISOFLURANE (±)-Difluormethoxy-1-chlor-2,2,2-trifluorethan Abbott/B506 -
(Abbott, Illinois, USA; Sigma-Aldrich, St. Louis, USA; Tocris, Bristol, UK)
42
